BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Andrea Apolo
So there are additional trials that had this similar approach where they gave neoadjuvant cisplatinase-based chemotherapy with a checkpoint, and then there was an adjuvant component. So I think reading, I think the outcome of those trials will be super important. But for now, I mean, I think that we have to consider this a new standard of care. I mean, patients did so well.
0
💬
0
Comments
Log in to comment.
There are no comments yet.